Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing the immunotherapy | The company's Emerald-3 study showed a 30% reduction in the risk of disease progression or death among embolization-eligible liver cancer patients who used an Imfinzi and Imjudo regimen.
1,002 words~5 min read
